IP Library Granted Patent US 8,771,737
Granted Patent B2
US 8,771,737 · App. 13/732,718 · Granted Jul 8, 2014

Compositions for regenerating defective or absent myocardium

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,771,737
App. No.
13/732,718
Granted
Jul 8, 2014
Kind
B2
Abstract

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Claims (20)

1. An injectable graft composition for myocardial tissue regeneration, said composition comprising an acellular extracellular matrix (ECM) from a mammalian tissue source comprising small intestine submucosa, said ECM comprising endogenous proteoglycans, fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), said ECM further comprising an exogenously added transforming growth factor-β (TGF-β), said TGF-β comprising at least 0.1% by weight of said composition,

said TGF-β being linked to at least one molecule in said ECM, wherein said TGF-β interacts with said proteoglycans to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.

2. The composition of claim 1 , wherein said composition further comprises an exogenously added cytokine.

3. An injectable graft composition for myocardial tissue regeneration, said composition comprising an acellular extracellular matrix (ECM) from a mammalian tissue source comprising urinary bladder submucosa, said ECM comprising endogenous proteoglycans, fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), said ECM further comprising an exogenously added transforming growth factor-β (TGF-β), said TGF-β comprising at least 0.1% by weight of said composition,

said TGF-β being linked to at least one molecule in said ECM, wherein said TGF-β interacts with said proteoglycans to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.

4. The composition of claim 3 , wherein said composition further comprises an exogenously added cytokine.

5. An injectable graft composition for myocardial tissue regeneration, said composition comprising an acellular extracellular matrix (ECM) from a mammalian tissue source comprising stomach submucosa, said ECM comprising endogenous proteoglycans, fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), said ECM further comprising an exogenously added transforming growth factor-β (TGF-β), said TGF-β comprising at least 0.1% by weight of said composition,

said TGF-β being linked to at least one molecule in said ECM, wherein said TGF-β interacts with said proteoglycans to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.

6. The composition of claim 5 , wherein said composition further comprises an exogenously added cytokine.

7. An injectable graft composition for myocardial tissue regeneration, said composition comprising an acellular extracellular matrix (ECM) from a mammalian tissue source comprising liver basement submucosa, said ECM comprising endogenous proteoglycans, fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), said ECM further comprising an exogenously added transforming growth factor-β(TGF-β), said TGF-β comprising at least 0.1% by weight of said composition, said TGF-β being linked to at least one molecule in said ECM, wherein said TGF-β interacts with said proteoglycans to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.

8. The composition of claim 7 , wherein said composition further comprises an exogenously added cytokine.

9. An injectable graft composition for myocardial tissue regeneration, said composition comprising an acellular extracellular matrix (ECM) from a mammalian tissue source comprising liver basement membrane, said ECM comprising endogenous proteoglycans, fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), said ECM further comprising an exogenously added transforming growth factor-β (TGF-β), said TGF-β comprising at least 0.1% by weight of said composition,

said TGF-β being linked to at least one molecule in said ECM, wherein said TGF-β interacts with said proteoglycans to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.

10. The composition of claim 9 , wherein said composition further comprises an exogenously added cytokine.

11. An injectable graft composition for myocardial tissue regeneration, said composition comprising an acellular placental extracellular matrix (ECM), said ECM comprising endogenous proteoglycans, fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), said ECM further comprising an exogenously added transforming growth factor-β (TGF-β), said TGF-β comprising at least 0.1% by weight of said composition,

said TGF-β being linked to at least one molecule in said ECM, wherein said TGF-β interacts with said proteoglycans to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.

12. The composition of claim 11 , wherein said composition further comprises an exogenously added cytokine.

13. An injectable graft composition for myocardial tissue regeneration, said composition comprising an acellular heart extracellular matrix (ECM), said ECM comprising endogenous proteoglycans, fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), said ECM further comprising an exogenously added transforming growth factor-β (TGF-β), said TGF-β comprising at least 0.1% by weight of said composition,

said TGF-β being linked to at least one molecule in said ECM, wherein said TGF-β interacts with said proteoglycans to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.

14. The composition of claim 13 , wherein said composition further comprises an exogenously added cytokine.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2017
From: MIDCAP FINANCIAL TRUST
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 042669/0559 →
SECURITY INTEREST Recorded Sep 30, 2015
From: CORMATRIX CARDIOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 036732/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2013
From: MATHENY, ROBERT G
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 031787/0679 →